Quality by Design: Building Reliable Clinical Trial Execution from Day One

Start with what must go right

Critical-to-quality factors are aspects of the trial that are fundamental to protecting participants and producing reliable, interpretable results. At the site level, examples may include valid consent, correct eligibility, accurate dosing, timely safety escalation, endpoint assessments within protocol windows, sample integrity, and traceable source data.

The exact list should come from the protocol and trial design. A pharmacokinetic endpoint may make collection time and processing especially critical. A biomarker-selected cohort may make tissue identity, assay requirements, and central confirmation critical. A blinded comparison may make treatment concealment and emergency unblinding controls critical.

Convert the protocol into an operating map

A protocol is not yet a workflow. Before activation, the team should map:

• •Who performs, verifies, and documents each critical activity
• •What information must be available before a decision
• •Where handoffs occur between investigator, coordinator, nursing, pharmacy, laboratory, data, and external vendors
• •Which activities have strict windows or sequencing
• •What constitutes an exception and who can decide what happens next
• •Which source records demonstrate that the requirement was met

Use the schedule of activities as a starting point, then add operational details. A mock patient journey or rehearsal can reveal conflicts that are not obvious during document review.

Design eligibility as a controlled decision

Eligibility errors can expose participants to inappropriate risk and undermine study data. A robust process may include a criterion-by-criterion checklist linked to source evidence, independent verification of selected high-risk criteria, confirmation that late-arriving results were reviewed, and documented investigator approval before enrollment or randomization.

The control should account for protocol amendments and clarifications. Teams need a reliable way to know which version governs the decision and whether retraining or revised tools are required.

Build safety escalation before it is needed

The site should define how symptoms, laboratory abnormalities, serious adverse events, dose-limiting toxicities, and urgent medical questions move from discovery to clinical assessment and required reporting. The path must work after hours and when primary staff are unavailable.

Important design questions include:

• •Who receives the first call?
• •How is the investigator reached?
• •What information is collected immediately?
• •Which reporting clock may have started?
• •How is follow-up information tracked?
• •How are the treating physician and emergency clinicians involved when appropriate?

Contact lists alone are not enough. Staff need scenario-based training and documented backup coverage.

Protect investigational product and sample integrity

Product and specimen workflows often depend on precise conditions. Pharmacy controls may address receipt, temperature, access, preparation, dose calculation, accountability, returns, and destruction. Laboratory controls may address collection tubes, timestamps, centrifugation, aliquoting, labeling, temperature, storage, courier cutoffs, and shipment documentation.

Map the worst practical days: an early morning draw, a delayed infusion, a weekend visit, equipment failure, late courier, or temperature excursion. Preparedness is strongest when the contingency has an owner and a documented response path.

Use data to detect drift

Quality signals should help the site act before a pattern becomes systemic. Useful measures depend on the study but may include:

• •Consent or eligibility corrections
• •Visit-window pressure and missed procedures
• •Sample collection or shipment issues
• •Query aging and recurring data discrepancies
• •Protocol deviations by type and root cause
• •Safety-reporting timeliness
• •Training completion and amendment implementation
• •Staff workload and coverage gaps

Metrics should lead to decisions. A dashboard with no threshold, owner, or action pathway is only decoration.

Corrective action should improve the system

When an issue occurs, contain immediate risk, understand scope, identify contributing causes, and decide whether corrective and preventive action is needed. “Retrain the coordinator” may be insufficient if the real cause is an ambiguous order set, conflicting tools, unrealistic scheduling, or weak investigator access.

Effectiveness checks should show whether the change worked. Lessons from deviations, monitoring, audits, and near misses should feed back into templates, training, feasibility, and future study setup.

Our FCTG approach

At FCTG, we apply a Quality by Design lens from protocol feasibility through startup and execution. Our physician investigators and quality and operations leaders identify requirements critical to participant safety and data reliability. Our team then assigns operational ownership and verifies whether our staffing, investigator access, pharmacy, laboratory, data, and referral workflows can support the study. We adapt our controls to each protocol rather than applying one generic package.